drug_development
The latest news about drug_development: headlines, AI summaries and the full story from every source.
- Bristol Myers Squibb Shares Rise on Positive Phase 3 Trial Results
- Kodiak Sciences Shares Surge After Positive Phase 3 Trial Results for Wet AMD Treatments
- Acadia Pharmaceuticals Shares Drop Following Disappointing Drug Trial Results
- Arcturus Reports Positive Mid-Stage Trial Results for ARCT-810 in OTC Deficiency
- ProKidney Completes Enrollment for Pivotal Kidney Therapy Trial
- Novartis Shares Fall After Key Clinical Trial Failures
- Pharvaris Reports Positive Late-Stage Trial Results for HAE Drug
- Ultragenyx Shares Drop After Phase 3 Trial for Apazunersen Fails to Meet Key Endpoints
- Biohaven Licenses Epilepsy Candidate Opakalim for $795 Million
- AstraZeneca and Hutchmed Report Positive Results from Lung Cancer Trial
- Tenax Therapeutics Reports Subgroup Benefit Despite Phase 3 Trial Missing Primary Endpoint
- Eli Lilly's Olomorasib Receives FDA Breakthrough Therapy Designation for Pancreatic Cancer
- Preclinical Studies of Narmafotinib in Pancreatic Cancer Published Online
- Atea Pharmaceuticals Reports Positive Phase 3 Trial Results for Hepatitis C Treatment
- Trevi Therapeutics Shares Rise on Positive Haduvio Clinical Trial Results
- Spero Therapeutics Secures $105M Financing from KKR Affiliate
- Vertex Pharmaceuticals Acquires Crinetics for $10 Billion
- Eli Lilly Announces Positive Phase 3 Results for Jaypirca Combination Therapy in Relapsed or Refractory CLL/SLL
- International Regulatory Pathways Support Drug Development in Biotech and Pharma
- Mirum Pharmaceuticals Reports Positive Phase 2b Data for Volixibat in PSC
- Praxis Precision Medicines Shares Phase 2/3 POWER1 Study Findings
- CytomX Reports Q4 2025 Earnings and Phase I Trial Data for Varseta-M
- Praxis Precision Medicines Shares Drop After Phase 2/3 Trial of Seizure Drug Fails Primary Endpoint
- Oculis Shares Drop Following Phase 3 Trial Failures
- Lantern Pharma Provides Q1 2025 Earnings Update
- BioMarin's Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint
- Mineralys (MLYS) Q1 2026 Earnings Call Summary